Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice
Open accessThe DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the role of glucagon action in the metabolic phenotype of untreated insulin deficiency. RESEARCH DESIGN AND METHODS: We compared pertinent clinical and metabolic parameters in glucagon receptor-null (Gcgr−/−) mice and wild-type (Gcgr+/+) controls after equivalent destruction of β-cells. We used a double dose of streptozotocin to maximize β-cell destruction. RESULTS: Gcgr+/+ mice became hyperglycemic (>500 mg/dL), hyperketonemic, polyuric, and cachectic and had to be killed after 6 weeks. Despite comparable β-cell destruction in Gcgr−/− mice, none of the foregoing clinical or laboratory manifestations of diabetes appeared. There was marked α-cell hyperplasia and hyperglucagonemia (∼1,200 pg/mL), but hepatic phosphorylated cAMP response element binding protein and phosphoenolpyruvate carboxykinase mRNA were profoundly reduced compared with Gcgr+/+ mice with diabetes—evidence that glucagon action had been effectively blocked. Fasting glucose levels and oral and intraperitoneal glucose tolerance tests were normal. Both fasting and nonfasting free fatty acid levels and nonfasting β-hydroxy butyrate levels were lower. CONCLUSIONS: We conclude that blocking glucagon action prevents the deadly metabolic and clinical derangements of type 1 diabetic mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While lack of GCGR signaling can normalize glycemia under insulin-deficient conditions15,16, this effect is contingent on the presence of residual insulin17.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値
Whittaker, P. G., Morgan, M. R., Dean, P., Cameron, E., & Lind, T. (1980) · The Lancet · Cited by 724
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599 · cited 1×
“This idea was proposed previously (9,10) when somatostatin, the first glucagon-suppressing agent to be discovered (6), was found to prevent the acute metabolic consequences of complete insulin lack (7,8).”
BackgroundSelf-citationGelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563 · cited 5×
“Male mice with global glucagon receptor knockout and wild-type mice (19)”
BackgroundSelf-citationGerich, J. E., Lorenzi, M., Bier, D. M., Schneider, V., Tsalikian, E., Karam, J. H., & Forsham, P. H. (1975) · New England Journal of Medicine · doi:10.1056/nejm197505082921901 · Cited by 354 · cited 1×
“This idea was proposed previously (9,10) when somatostatin, the first glucagon-suppressing agent to be discovered (6), was found to prevent the acute metabolic consequences of complete insulin lack (7,8).”
BackgroundTHE EFFECTS OF TOTAL STARVATION UPON THE LEVELS OF CIRCULATING GLUCAGON AND INSULIN IN MAN*
Unger, R. H., Eisentraut, A. M., & Madison, L. L. (1963) · Journal of Clinical Investigation · doi:10.1172/jci104788 · Cited by 345 · cited 1×
“Glucagon was immunocytochemically localized to pancreatic a-cells (3) and shown to be secreted in response to increased glucose need, as in starvation and exercise (4).”
BackgroundSelf-citationLeptin therapy in insulin-deficient type I diabetes
Wang, M.-Y., Chen, L., Clark, G. O., Lee, Y., Stevens, R. D., Ilkayeva, O. R., Wenner, B. R., Bain, J. R., Charron, M. J., Newgard, C. B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909422107 · Cited by 327 · cited 6×
“The search for more practical suppressors or antagonists of glucagon has been reenergized by the recent demonstration that leptin can suppress diabetic hyperglucagonemia and reverse the catabolic effects of complete insulin deficiency for extended periods without apparent negative consequences (11,12).”
BackgroundResultSelf-citationCREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-γ
Herzig, S., Hedrick, S., Morantte, I., Koo, S.-H., Galimi, F., & Montminy, M. (2003) · Nature · doi:10.1038/nature02110 · Cited by 321 · cited 2×
“Uncontrolled insulin deficiency with hyperglucagonemia is characterized by increased gluconeogenesis associated with upregulation of the gluconeogenic enzyme, phosphoenolpyruvate carboxykinase (PEPCK) (29,30).”
BackgroundInsulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303 · cited 1×
“In contrast to normal a-cells, which are restrained by the high local concentrations of intraislet insulin (22), type 1 diabetic a-cells are unregulated, which results in inappropriate hyperglucagonemia (5).”
BackgroundSelf-citationAntidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Hedbacker, K., Birsoy, K., Wysocki, R. W., Asilmaz, E., Ahima, R. S., Farooqi, I. S., & Friedman, J. M. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.11.007 · Cited by 280 · cited 2×
“More recently, the same antidiabetic efficacy has been demonstrated with recombinant leptin (11,23).”
BackgroundUnger, R. H., Eisentraut, A. M., McCall, M. S., & Madison, L. L. (1962) · Journal of Clinical Investigation · doi:10.1172/jci104525 · Cited by 278 · cited 1×
“The development of a radioimmunoassay for glucagon (1) established the hormonal status of this peptide (2), originally considered to be a contaminant of the insulin extraction process.”
BackgroundSelf-citation
Cited by
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Energy Metabolism in the Liver
Rui, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130024 · Cited by 1,953
Stern, J. H., Rutkowski, J. M., & Scherer, P. E. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.04.011 · Cited by 1,031
“Hence, inhibition of hepatic gluconeogenesis appears to provide a promising intervention to treat insulin resistance and related metabolic disorders (Lee et al., 2011; Wang et al., 2015).”
BackgroundGlucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670
Self-citationGuo, S. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0327 · Cited by 623
“On the other hand, antagonizing glucagon receptor action in type 1 diabetes induced by streptozotocin and type 2 diabetes mellitus in mice markedly reduced blood glucose levels and completely prevented diabetes (Liang et al. 2004, Sorensen et al. 2006, Ali & Drucker 2009, Lee et al. 2011).”
BackgroundRegulation of Insulin Secretion in Human Pancreatic Islets
Rorsman, P., & Braun, M. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183754 · Cited by 599
Unraveling the Regulation of Hepatic Metabolism by Insulin
Titchenell, P. M., Lazar, M. A., & Birnbaum, M. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.03.003 · Cited by 437
“Surprisingly, the metabolic abnormalities associated with streptozotocininduced insulin deficiency are abrogated by loss of the glucagon receptor [67,68].”
BackgroundGABA exerts protective and regenerative effects on islet beta cells and reverses diabetes
Soltani, N., Qiu, H., Aleksic, M., Glinka, Y., Zhao, F., Liu, R., Li, Y., Zhang, N., Chakrabarti, R., Ng, T., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102715108 · Cited by 417
“(33) demonstrated that glucagon receptor-KO mice are resistant to STZ-induced diabetes.”
BackgroundDirect and indirect effects of leptin on adipocyte metabolism
Harris, R. B. S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.05.009 · Cited by 316
“Recently it has been reported that knockout of the glucagon receptor prevents development of Type 1 diabetes in STZ-treated mice [165] which is consistent with evidence that leptin down-regulates glucagon in vivo in type 1 diabetic mice [164] and that physiological concentrations of leptin depolarize alpha cells and s…”
BackgroundThe Cells of the Islets of Langerhans
Da Silva Xavier, G. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7030054 · Cited by 295
Leptin revisited: its mechanism of action and potential for treating diabetes
Coppari, R., & Bjørbæk, C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3757 · Cited by 293
Reversal of Type 1 Diabetes in Mice by Brown Adipose Tissue Transplant
Gunawardana, S. C., & Piston, D. W. (2012) · Diabetes · doi:10.2337/db11-0510 · Cited by 290
“Thus, suppression of glucagon may be a key mechanism of glucose homeostasis that becomes even more important in the absence of insulin, as has also been reported in recent studies (20,21).”
BackgroundResultIslet α cells and glucagon--critical regulators of energy homeostasis
Campbell, J. E., & Drucker, D. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.51 · Cited by 266
KATP channels and islet hormone secretion: new insights and controversies
Ashcroft, F. M., & Rorsman, P. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.166 · Cited by 272
Minireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in Diabetes
Cryer, P. E. (2012) · Endocrinology · doi:10.1210/en.2011-1499 · Cited by 242
Regulation of calcium in pancreatic α- and β-cells in health and disease
Rorsman, P., Braun, M., & Zhang, Q. (2012) · Cell Calcium · doi:10.1016/j.ceca.2011.11.006 · Cited by 220
The glucoregulatory actions of leptin
D'souza, A. M., Neumann, U. H., Glavas, M. M., & Kieffer, T. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.011 · Cited by 216
Brereton, M. F., Vergari, E., Zhang, Q., & Clark, A. (2015) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415583535 · Cited by 206
“The importance of targeting and correcting the glucagon secretory defect is exemplified in mice where genetic deletion of the glucagon receptor prevents the development of diet-induced obesity and streptozotocininduced diabetes (Conarello et al. 2007; Lee et al. 2011).”
BackgroundTian, J., Dang, H. N., Yong, J., Chui, W.-S., Dizon, M. P. G., Yaw, C. K. Y., & Kaufman, D. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025338 · Cited by 198
Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones
Geisler, C. E., & Renquist, B. J. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0513 · Cited by 191
Jiang, S., Young, J., Wang, K., Qian, Y., & Cai, L. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11175 · Cited by 186
“…and glycogenolysis (60). in animal experiments, the inhibition of glucagon action prevented the metabolic disorders noted in T1dM mice (67). another study indicated that moderately controlled patients with T1dM exhibited increased glucose production during both rest and exercise,…”
Regulation of glucagon secretion by glucose: paracrine, intrinsic or both?
Walker, J. N., Ramracheya, R., Zhang, Q., Johnson, P. R. V., Braun, M., & Rorsman, P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01450.x · Cited by 176
GLP-1/glucagon receptor co-agonism for treatment of obesity
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175
“Furthermore, mice made diabetic by streptozotocin (STZ) administration, but genetically deficient for the GcgR, display normal glucose tolerance [49].”
BackgroundGlucagon is the key factor in the development of diabetes
Lee, Y. H., Wang, M.-Y., Yu, X.-X., & Unger, R. H. (2016) · Diabetologia · doi:10.1007/s00125-016-3965-9 · Cited by 166
“These studies suggest that glucagon is essential for hyperglycaemia in type 1 diabetes and that blocking glucagon action prevents deadly metabolic and clinical derangements [5, 6] (Table 1).”
Self-citationThe Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
“Transgenic mice lacking the glucagon receptor do not develop diabetes, even after nearly-complete beta-cell destruction.(21,22) However, this finding has not been confirmed by other groups.”
BackgroundThe role of leptin in health and disease
Ramos-Lobo, A. M., & Donato, J. (2017) · Temperature · doi:10.1080/23328940.2017.1327003 · Cited by 160
Ginsenoside Rg1 Inhibits Glucagon-Induced Hepatic Gluconeogenesis through Akt-FoxO1 Interaction
Liu, Q., Zhang, F.-G., Zhang, W., Pan, A., Yang, Y., Liu, J., Li, P., Liu, B., & Qi, L. (2017) · Theranostics · doi:10.7150/thno.18788 · Cited by 158
“Gene knockout of glucagon receptor in diabetic mice prevents metabolic consequences, further confirming that glucagon is indispensable in the development of diabetes [7].”
BackgroundTargeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
PAX6 maintains β cell identity by repressing genes of alternative islet cell types
Swisa, A., Avrahami, D., Eden, N., Zhang, J., Feleke, E., Dahan, T., Cohen-Tayar, Y., Stolovich-Rain, M., Kaestner, K. H., Glaser, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci88015 · Cited by 152
The Liver–α-Cell Axis and Type 2 Diabetes
Wewer Albrechtsen, N. J., Pedersen, J., Galsgaard, K. D., Winther-Sørensen, M., Suppli, M. P., Janah, L., Gromada, J., Vilstrup, H., Knop, F. K., & Holst, J. J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00251 · Cited by 149
Metabolic manifestations of insulin deficiency do not occur without glucagon action
Lee, Y., Berglund, E. D., Wang, M.-Y., Fu, X., Yu, X., Charron, M. J., Burgess, S. C., & Unger, R. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205983109 · Cited by 151
“In confirmation of our earlier report (26), β-cell destruction in the GcgR mice did not alter the postprandial glucose levels (Fig.”
BackgroundMethodInfluentialSelf-citationThe role of leptin in glucose homeostasis
Denroche, H. C., Huynh, F. K., & Kieffer, T. J. (2012) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2012.00203.x · Cited by 146
Targeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 156
Alkhalidy, H., Moore, W., Wang, Y., Luo, J., McMillan, R. P., Wei, Z., Zhou, K., & Liu, D. (2018) · Molecules · doi:10.3390/molecules23092338 · Cited by 151
“Indeed, the use of agents that suppress glucagon [18] or its action can prevent hyperglycemia in insulin-deficient rodent models of diabetes [19].”
BackgroundThe Biology of Glucagon and the Consequences of Hyperglucagonemia
Wewer Albrechtsen, N. J., Kuhre, R. E., Pedersen, J., Knop, F. K., & Holst, J. J. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0090 · Cited by 129
Gut-liver interaction in triglyceride-rich lipoprotein metabolism
Xiao, C., Hsieh, J., Adeli, K., & Lewis, G. F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00178.2011 · Cited by 127
Glucagon – Early breakthroughs and recent discoveries
Åhrén, B. (2015) · Peptides · doi:10.1016/j.peptides.2015.03.011 · Cited by 134
Glucagon and Type 2 Diabetes: the Return of the Alpha Cell
Lund, A., Bagger, J. I., Christensen, M., Knop, F. K., & Vilsbøll, T. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0555-4 · Cited by 144
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
The role of leptin in diabetes: metabolic effects
Meek, T. H., & Morton, G. J. (2016) · Diabetologia · doi:10.1007/s00125-016-3898-3 · Cited by 132
“CRR Counter-regulatory response HGP Hepatic glucose production i.c.v Intracerebroventricular POMC Pro-opiomelanocortin STZ Streptozotocin STZ-DM Streptozotocin-induced diabetes mellitus uDM Uncontrolled insulin-deficient diabetes VMN Ventromedial nucleus Leptin regulation of glucose metabolism Growing evidence suggest…”
BackgroundInfluentialNormal Glucagon Signaling and β-Cell Function After Near-Total α-Cell Ablation in Adult Mice
Thorel, F., Damond, N., Chera, S., Wiederkehr, A., Thorens, B., Meda, P., Wollheim, C. B., & Herrera, P. L. (2011) · Diabetes · doi:10.2337/db11-0876 · Cited by 119
“Inhibition of glucagon signaling (GcgR mice) was recently shown to prevent STZ-induced diabetes (6).”
BackgroundResultInfluentialRepositioning Glucagon Action in the Physiology and Pharmacology of Diabetes
Finan, B., Capozzi, M. E., & Campbell, J. E. (2020) · Diabetes · doi:10.2337/dbi19-0004 · Cited by 118
Wang, M.-Y., Yan, H., Shi, Z., Evans, M. R., Yu, X., Lee, Y., Chen, S., Williams, A., Philippe, J., Roth, M. G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424934112 · Cited by 112
Self-citationKelly, R. P., Garhyan, P., Raddad, E., Fu, H., Lim, C. N., Prince, M. J., Pinaire, J. A., Loh, M. T., & Deeg, M. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12446 · Cited by 110
Short Chain Fatty Acids, pancreatic dysfunction and type 2 diabetes
Mandaliya, D. K., & Seshadri, S. (2019) · Pancreatology · doi:10.1016/j.pan.2019.01.021 · Cited by 110
The past, present, and future physiology and pharmacology of glucagon
Capozzi, M. E., D’Alessio, D. A., & Campbell, J. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.10.001 · Cited by 109
Sheng, L., Zhou, Y., Chen, Z., Ren, D., Cho, K. W., Jiang, L., Shen, H., Sasaki, Y., & Rui, L. (2012) · Nature Medicine · doi:10.1038/nm.2756 · Cited by 107
Okamoto, H., Kim, J., Aglione, J., Lee, J., Cavino, K., Na, E., Rafique, A., Kim, J. H., Harp, J., Valenzuela, D. M., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1011 · Cited by 100
The role of glucagon on type 2 diabetes at a glance
Godoy-Matos, A. F. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-91 · Cited by 99
“complete beta-cell destruction [38].”
Novel Mechanism of Foxo1 Phosphorylation in Glucagon Signaling in Control of Glucose Homeostasis
Wu, Y., Pan, Q., Yan, H., Zhang, K., Guo, X., Xu, Z., Yang, W., Qi, Y., Guo, C., Hornsby, C., et al. (2018) · Diabetes · doi:10.2337/db18-0674 · Cited by 103
“Given that a high glucagon level is present in both types of diabetes (6), hyperactivation of Foxo1 by activated PKA and inactivated Akt upon insulin resistance or deficiency may serve as fundamental mechanisms for excess liver gluconeogenesis resulting in diabetic hyperglycemia.”
BackgroundHyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells
Lee, Y., Berglund, E. D., Yu, X., Wang, M.-Y., Evans, M. R., Scherer, P. E., Holland, W. L., Charron, M. J., Roth, M. G., & Unger, R. H. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409638111 · Cited by 96
“It has recently been shown that glucagon receptor-null mice remain normoglycemic and nonketotic despite total insulin deficiency but that transduction of a glucagon receptor cDNA into their liver makes them severely diabetic (15, 16).”
BackgroundSelf-citationInsulin and Glucagon: Partners for Life
Holst, J. J., Holland, W., Gromada, J., Lee, Y., Unger, R. H., Yan, H., Sloop, K. W., Kieffer, T. J., Damond, N., & Herrera, P. L. (2017) · Endocrinology · doi:10.1210/en.2016-1748 · Cited by 90
“(25) from the laboratory of Roger Unger reported that inGcgrmice [developed byGelling et al.”
BackgroundSelf-citationObesity dysregulates fasting-induced changes in glucagon secretion
Stern, J. H., Smith, G. I., Chen, S., Unger, R. H., Klein, S., & Scherer, P. E. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0201 · Cited by 84
Self-citationThe molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
α-cell role in β-cell generation and regeneration
Habener, J. F., & Stanojevic, V. (2012) · Islets · doi:10.4161/isl.20500 · Cited by 99
Regulation of chylomicron production in humans
Xiao, C., & Lewis, G. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.019 · Cited by 91
Omar, B. A., Andersen, B., Hald, J., Raun, K., Nishimura, E., & Ahrén, B. (2014) · Diabetes · doi:10.2337/db13-0710 · Cited by 76
“Recently, this same group revisited the physiological consequences of suppression of glucagon action in near totally insulin deficient states using mice with glucagon receptor deficiency (5; 27).”
InfluentialGlucagon secretion and signaling in the development of diabetes
Gaisano, H. Y., MacDonald, P. E., & Vranic, M. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00349 · Cited by 75
“Recently, studies in glucagon receptor-null mice (Gcgr−/−) indicate that glucagon mediates the metabolic consequences of insulin lack (Lee et al., 2011).”
BackgroundBlockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist
Damond, N., Thorel, F., Moyers, J. S., Charron, M. J., Vuguin, P. M., Powers, A. C., & Herrera, P. L. (2016) · eLife · doi:10.7554/elife.13828 · Cited by 74
“Although STZ-treated Gcgr-/- mice remained normoglycemic, as previously reported (Conarello et al., 2006; Lee et al., 2011; 2012), they developed severe hyperglycemia after insulin receptor inhibition (continuous vs dotted purple line).”
InfluentialSelf-citationLiu, S., Kilic, G., Meyers, M. S., Navarro, G., Wang, Y., Oberholzer, J., & Mauvais-Jarvis, F. (2013) · Diabetologia · doi:10.1007/s00125-012-2764-1 · Cited by 73
“Indeed, total insulin deficiency by beta cell destruction in glucagon-receptor-null mice, which are unresponsive to glucagon, does not cause diabetic abnormalities [41].”
BackgroundRegulation of islet glucagon secretion: Beyond calcium
Hughes, J. W., Ustione, A., Lavagnino, Z., & Piston, D. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13381 · Cited by 73
Diabetes-related alterations in the enteric nervous system and its microenvironment
Bagyánszki, M. (2012) · World Journal of Diabetes · doi:10.4239/wjd.v3.i5.80 · Cited by 71
Brun, P., Grijalva, A., Rausch, R. N., Watson, E., Yuen, J. J., Das, B. C., Shudo, K., Kagechika, H., Leibel, R. L., & Blaner, W. S. (2014) · The FASEB Journal · doi:10.1096/fj.14-256743 · Cited by 79
“These studies have highlighted the nominal importance of endogenous b-cell function in the suppression of glucagon secretion after glucose administration and suggest that an insufficient decline in glucagon levels after glucose administration to b-cell–deficient mice is primarily due to functional impairment of intrai…”
BackgroundMitoNEET-Parkin Effects in Pancreatic α- and β-Cells, Cellular Survival, and Intrainsular Cross Talk
Kusminski, C. M., Chen, S., Ye, R., Sun, K., Wang, Q. A., Spurgin, S. B., Sanders, P. E., Brozinick, J. T., Geldenhuys, W. J., Li, W.-H., et al. (2016) · Diabetes · doi:10.2337/db15-1323 · Cited by 69
“Mice lacking proper glucagon signaling post streptozotocininduced loss of b-cell mass do not develop diabetes (67,68).”
BackgroundSelf-citationZeng, Z., Huang, S., & Sun, T. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00922-x · Cited by 78
Watanabe, C., Seino, Y., Miyahira, H., Yamamoto, M., Fukami, A., Ozaki, N., Takagishi, Y., Sato, J., Fukuwatari, T., Shibata, K., et al. (2012) · Diabetes · doi:10.2337/db11-0739 · Cited by 67
“While the current manuscript was in preparation, it was reported that the concentration of amino acids is increased in the liver of glucagon receptor knockout mice (34).”
BackgroundLack of glucagon receptor signaling and its implications beyond glucose homeostasis
Charron, M. J., & Vuguin, P. M. (2015) · Journal of Endocrinology · doi:10.1530/joe-14-0614 · Cited by 68
“Disruption of the Gcgr gene in an insulin-deficient diabetic rodent model is accompanied by an asymptomatic, benign, non-catabolic state when followed for 6 weeks (Conarello et al. 2007, Lee et al. 2011), suggesting that ‘other factors’ contribute to the normalization of the catabolic state.”
Self-citationPancreatic α-cells – The unsung heroes in islet function
Wendt, A., & Eliasson, L. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.01.006 · Cited by 87
Karimian, N., Qin, T., Liang, T., Osundiji, M., Huang, Y., Teich, T., Riddell, M. C., Cattral, M. S., Coy, D. H., Vranic, M., et al. (2013) · Diabetes · doi:10.2337/db13-0164 · Cited by 66
The Alpha-Cell as Target for Type 2 Diabetes Therapy
Christensen, M., Bagger, J. I., Vilsboll, T., & Knop, F. K. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.369 · Cited by 65
“A very recent and remarkable finding by Unger and co-workers was the observation that streptozotocin-induced beta-cell destruction did not cause the expected hyperglycemic and catabolic disorders in Gcgr mice [35].”
BackgroundAlpha-cell paracrine signaling in the regulation of beta-cell insulin secretion
Holter, M. M., Saikia, M., & Cummings, B. P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.934775 · Cited by 63
“Certainly, independent groups have demonstrated that mice with marked alpha-cell hyperplasia and hyperglucagonemia secondary to whole-body GCGR knockout are resistant to the metabolic manifestations of betacell destruction (103, 104); however, evidence suggests that this resistance is mediated by compensatory increase…”
BackgroundAlpha cell dysfunction in type 1 diabetes
Yosten, G. L. C. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.001 · Cited by 62
Xiao, N., Lou, M., Lu, Y., Yang, L., Liu, Q., Liu, B., Qi, L., & Li, P. (2017) · Diabetologia · doi:10.1007/s00125-017-4238-y · Cited by 62
“Total beta cell destruction fails to induce diabetes in glucagon receptor knockout mice [5], indicating that glucagon dysregulation is the sine qua non of diabetes.”
BackgroundJun, L. S., Millican, R. L., Hawkins, E. D., Konkol, D. L., Showalter, A. D., Christe, M. E., Michael, M. D., & Sloop, K. W. (2015) · Diabetes · doi:10.2337/db14-1052 · Cited by 60
“To cause maximal b-cell loss, Unger and colleagues (16) established a high-dose STZ treatment regimen that resulted in nearly complete b-cell destruction in Gcgr mice.”
BackgroundMethodResultInfluentialStructural meta-analysis of regular human insulin in pharmaceutical formulations
Fávero-Retto, M. P., Palmieri, L. C., Souza, T. A. C. B., Almeida, F. C. L., & Lima, L. M. T. R. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.05.005 · Cited by 59
Glucagon actions on the kidney revisited: possible role in potassium homeostasis
Bankir, L., Bouby, N., Blondeau, B., & Crambert, G. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00560.2015 · Cited by 61
“These mice exhibit a reduced blood glucose concentration (74, 173) and fail to become hyperglycemic after streptozotocin administration (61, 100, 134, 198).”
BackgroundGlucagon's Metabolic Action in Health and Disease
Zeigerer, A., Sekar, R., Kleinert, M., Nason, S., Habegger, K. M., & Müller, T. D. (2021) · Comprehensive Physiology · doi:10.1002/cphy.c200013 · Cited by 59
Regulation of amino acid metabolism and α‐cell proliferation by glucagon
Hayashi, Y., & Seino, Y. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12797 · Cited by 59
Habener, J. F., & Stanojevic, V. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.10.009 · Cited by 61
Glucagon orchestrates stress‐induced hyperglycaemia
Harp, J. B., Yancopoulos, G. D., & Gromada, J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12668 · Cited by 61
Iori, E., Vinci, B., Murphy, E., Marescotti, M. C., Avogaro, A., & Ahluwalia, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034704 · Cited by 56
Role of Glucagon and Its Receptor in the Pathogenesis of Diabetes
Jia, Y., Liu, Y., Feng, L., Sun, S., & Sun, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.928016 · Cited by 68
“When b cells of Gcgr -/- mice were destroyed by streptozotocin (STZ) and insulin secretion was inhibited, animals did not develop hyperglycemia, suggesting that Gcgr -/- mice do not develop T1D, even under a state of insulin deficiency (24).”
BackgroundSpaeth, J. M., Hunter, C. S., Bonatakis, L., Guo, M. A., French, C. A., Slack, I. F., Hara, M., Fisher, S. E., Ferrer, J. P., Morrisey, E. E., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3635-3 · Cited by 54
“Lee et al have shown that inhibiting total glucagon action impedes the development of STZ-induced diabetes [41].”
Vater, A., Sell, S., Kaczmarek, P., Maasch, C., Buchner, K., Pruszyńska‐Oszmałek, E., Kolodziejski, P. A., Purschke, W. G., Nowak, K. W., Strowski, M. Z., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.444414 · Cited by 57
“Deletion of the glucagon receptor inmice resulted in protection from streptozotocin (STZ)-induced diabetes (6) and severe hyperglycemia appeared when the knock-out was reverted by adenoviral glucagon receptor expression (7).”
BackgroundMethodInfluentialNutrient regulation of glucagon secretion: involvement in metabolism and diabetes
Marroquí, L., Alonso-Magdalena, P., Merino, B., Fuentes, E., Nadal, A., & Quesada, I. (2014) · Nutrition Research Reviews · doi:10.1017/s0954422414000031 · Cited by 54
Problem or solution: The strange story of glucagon
Scott, R. V., & Bloom, S. R. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.013 · Cited by 54
“Compared to wild-type mice, Gcgr-/- mice have constitutively lower blood glucose levels, improved glucose homeostasis and a lean phenotype [41]; they are also resistant to the hyperglycaemic and hyperinsulinaemic effects of highfat diet, and following beta-cell destruction with streptozotocin, have normal glucose leve…”
BackgroundBlockade of Na+ Channels in Pancreatic α-Cells Has Antidiabetic Effects
Dhalla, A. K., Yang, M., Ning, Y., Kahlig, K. M., Krause, M., Rajamani, S., & Belardinelli, L. (2014) · Diabetes · doi:10.2337/db13-1562 · Cited by 53
“Therefore, suppression of glucagon secretion or inhibition of its action in the liver constitutes potential therapeutic targets for diabetes (30-32).”
Solomou, A., Meur, G., Bellomo, E. A., Hodson, D. J., Tomás, A., Migrenne, S., Philippe, E., Herrera, P. L., Magnan, C., & Rutter, G. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.645291 · Cited by 60
“Strikingly, mice deleted for glucagon receptors fail to develop hyperglycemia after the destruction of the -cell complement (5), demonstrating the likely importance of maintained or increased glucagon signaling in the context of type 2 diabetes (T2D)(4) (6, 7).”
BackgroundKumar, S., Patial, V., Soni, S., Sharma, S., Pratap, K., Kumar, D., & Padwad, Y. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00537 · Cited by 62
MafB Is Critical for Glucagon Production and Secretion in Mouse Pancreatic α Cells In Vivo
Katoh, M., Jung, Y., Ugboma, C. M., Shimbo, M., Kuno, A., Basha, W. A. A., Kudo, T., Oishi, H., & Takahashi, S. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00504-17 · Cited by 54
“Furthermore, glucagon receptor knockout mice are resistant to diabetes upon streptozotocin (STZ)-induced -cell destruction (42).”
BackgroundTranscriptional regulation of α ‐cell differentiation
Bramswig, N. C., & Kaestner, K. H. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01440.x · Cited by 62
Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control.
McCall, A. L., & Farhy, L. S. (2013) · PubMed · Cited by 80
Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status
Hu, C., Chen, Y., Yin, X., Xu, R., Yin, C., Wang, C., & Zhao, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02098-3 · Cited by 88
Ramakrishnan, S. K., Zhang, H., Takahashi, S., Centofanti, B., Periyasamy, S., Weisz, K., Chen, Z., Uhler, M. D., Rui, L., Gonzalez, F. J., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.004 · Cited by 51
Mu, J., Qureshi, S. A., Brady, E. J., Muise, E. S., Candelore, M. R., Jiang, G., Li, Z., Wu, M. S., Yang, X., Dallas-Yang, Q., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049572 · Cited by 50
“Hypoaminoacidemia, weight loss, and muscle wasting are key features of glucagonoma in humans [44]; conversely, lean body mass and circulating amino acids are increased in mice with targeted deletion of the GCGR gene [13,22,24,25,26].”
BackgroundEvolving function and potential of pancreatic alpha cells
Stanojevic, V., & Habener, J. F. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.10.002 · Cited by 59
EphA4 Receptor Forward Signaling Inhibits Glucagon Secretion From α-Cells
Hutchens, T., & Piston, D. W. (2015) · Diabetes · doi:10.2337/db15-0488 · Cited by 51
Potential role of non‐insulin adjunct therapy in Type 1 diabetes
George, P., & McCrimmon, R. J. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03744.x · Cited by 51
Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models
Vuguin, P. M., & Charron, M. J. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01447.x · Cited by 47
Self-citationGlucagon as a Critical Factor in the Pathology of Diabetes
Edgerton, D. S., & Cherrington, A. D. (2011) · Diabetes · doi:10.2337/db10-1594 · Cited by 47
“Unlike STZ treated wild-type Gcgr mice, which became severely hyperglycemic, STZ-treated mice lacking glucagon signaling appeared to be in a normal state of health and were completely protected from the manifestations of diabetes (1), as shown previously by the same group in alloxan treated Gcgr mice (3) and by Hancoc…”
BackgroundInfluential
Metadata
- Authors
- Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Albert Einstein College of Medicine (US)
- VA North Texas Health Care System (US)
- Corresponding author
- Unger, Roger H.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-01-21
- Volume
- 60
- Issue
- 2
- Pages
- 391-397
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3028337
- OpenAlex
- W1986861420
- Cited by
- 327
- References
- 47
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 12 · 2023: 14 · 2022: 19 · 2021: 20 · 2020: 12 · 2019: 16 · 2018: 25 · 2017: 26 · 2016: 32 · 2015: 40 · 2014: 25 · 2013: 23 · 2012: 26
- FWCI
- 32.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R21DK081194, DK081194)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon receptor, type 1 diabetes, insulin deficiency, beta cell destruction, streptozotocin, alpha cell hyperplasia, hyperglucagonemia, phosphoenolpyruvate carboxykinase, ketogenesis, hyperketonemia, glucose tolerance, free fatty acids, beta-hydroxybutyrate
- MeSH terms
- Animals, Blood Glucose, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 1, Enzyme-Linked Immunosorbent Assay, Fatty Acids, Glucagon, Hyperglycemia, Immunohistochemistry, Insulin, Insulin-Like Growth Factor I, Liver, Pancreas, Radioimmunoassay, Blotting, Western, Receptors, Glucagon, Mice, Knockout, Reverse Transcriptase Polymerase Chain Reaction, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.